Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (5600R)

TIDMHEMO

RNS Number : 5600R

Hemogenyx Pharmaceuticals PLC

09 March 2021

9 March 2021

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 94,882 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at an average price of 6.03p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,626,991 Ordinary Shares, representing approximately 0.36 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1.   Details of PDMR/person closely associated with them 
       ("PCA") 
 a)   Name                            Andrew Wright 
     ------------------------------  --------------------------------------------- 
 b)   Position/status                 PDMR: Financial Controller and Company 
                                       Secretary 
     ------------------------------  --------------------------------------------- 
 c)   Initial notification/           Initial notification 
       amendment 
     ------------------------------  --------------------------------------------- 
 2.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ----------------------------------------------------------------------------- 
 a)   Description of                  Ordinary shares of Hemogenyx Pharmaceuticals 
       the financial                   plc 
       instrument                      Identification code GB00BYX3WZ24 
     ------------------------------  --------------------------------------------- 
 b)   Nature of the                   Standalone acquisition of shares 
       transaction 
     ------------------------------  --------------------------------------------- 
 c)   Price(s) and volume(s)           Price(s)         Volume(s) 
                                        GBP GBP0.0603    94,882 
                                                        ---------- 
     ------------------------------  --------------------------------------------- 
 d)        Aggregated information      Price(s)           Volume(s) 
             *    Aggregated volume     GBP GBP5,721.38    94,882 
                                                          ---------- 
 
             *    Price 
     ------------------------------  --------------------------------------------- 
 e)   Date of the transaction         2021-03-08 
     ------------------------------  --------------------------------------------- 
 f)   Place of the transaction        London Stock Exchange 
                                       XLON 
     ------------------------------  --------------------------------------------- 
 

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   [e-mail] 
 Peter Redmond, Director                 [e-mail] 
 
                                         Tel: [phone] 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Adam Cowl 
 
                                         Tel: [phone] 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDBGDXGSGDGBI

(END) Dow Jones Newswires

March 09, 2021 02:00 ET (07:00 GMT)